Conference abstract · 23 Jun 2025
Conference abstractPublished 28 Nov 2016
Recombinant HBV vaccine enhances the rate of sustained virological response when initiated early after anti-HCV combination therapy
Zagazig University, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The overall SVR rate for chronic hepatitis C genotype 4 using the standard of care is 54.3%. HBV infection can be prevented by the administration of effective and safe vaccine. Evaluation of the vaccination-induced anti-HBs response rates in a cohort of HCV Egyptian patients after being exposed to antiviral combination therapy and the magnitude of its effect on the rate of SVR through its putative role in induction of crossed immunity. 500 HCV patients who had completed the course of antiviral therapy and achieved end of treatment response (ETR) were retrospectively analyzed and received 20 Ã?¼g of recombinant DNA vaccine for hepatitis B at time intervals (0, 1, 4 months). The first dose of the vaccine was initiated one month post treatment. Laboratory analysis included routine preliminary investigations to anti viral therapy and specific investigations as determination of anti-HBs antibodies 2 months following the third dose of vaccine. 433 patients showed protective response (86.6%), 67 patients were non responders (13.4%) (p=0.003). Adding HBV vaccine 1 month post treatment increased SVR (400 patients, 80%) (Chi-square=40.3, p=0.000). Diabetes affect response to HBV vaccine (p=0.0001). Adding HBV vaccine to the post treatment care of patients with HCV after termination of antiviral therapy gain two benefits; protection from HBV and significant increase in rates of SVR.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Antivirals & Antiretrovirals.
Conference abstract · 23 Jun 2025
Exploring signature proteins to design a novel multi-epitope vaccine candidate against Mycobacterium tuberculosis: An in-silico approach
Conference abstract · 23 Jun 2025
Correlation Between the Rh/ABO system and infection due to sars cov2 in morocco
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Antivirals & Antiretrovirals
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Amr Shaaban Hanafy”
